Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade-Reference-Cited by-同舟云学术

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Published:2017-04-12 Issue:385 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Schmittnaegel Martina¹^ORCID,Rigamonti Nicolò¹^ORCID,Kadioglu Ece¹,Cassará Antonino¹,Wyser Rmili Céline¹,Kiialainen Anna²,Kienast Yvonne³^ORCID,Mueller Hans-Joachim³,Ooi Chia-Huey²³,Laoui Damya¹^ORCID,De Palma Michele¹^ORCID

Affiliation:

1. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.

2. Roche Innovation Center Basel, Pharmaceutical Sciences, Pharma Research and Early Development, 4070 Basel, Switzerland.

3. Roche Innovation Center Munich, Oncology Discovery, Pharma Research and Early Development, 82377 Penzberg, Germany.

Abstract

Combination of antiangiogenic treatment and immune checkpoint inhibition improves antitumor immunity.

Funder

Leenaards Foundation

Swiss Cancer League

San Salvatore Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference66 articles.

1. Induction of angiogenesis during the transition from hyperplasia to neoplasia

2. Ten years of anti-vascular endothelial growth factor therapy

3. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

4. Modes of resistance to anti-angiogenic therapy

5. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities

Cited by 447 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

3. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications;Frontiers in Immunology;2024-09-03

4. Targeting the tumour vasculature: from vessel destruction to promotion;Nature Reviews Cancer;2024-08-29

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24